Bisacylimidoselenocarbamates Cause G2/M Arrest Associated with the Modulation of CDK1 and Chk2 in Human Breast Cancer MCF-7 Cells

Author(s): Iranzu Lamberto, Daniel Plano, Esther Moreno, Maria Font, Juan Antonio Palop, Carmen Sanmartin, Ignacio Encio.

Journal Name: Current Medicinal Chemistry

Volume 20 , Issue 12 , 2013

Submit Manuscript
Submit Proposal

Abstract:

Bisacylimidoselenocarbamate derivatives (BSC) are potent anticancer agents with a strong cytotoxic activity against different types of tumour cells. Based in phosphatidylserine exposure on the cell membranes we show that BSC treatment resulted in enhanced cell death in leukaemia CCRF-CEM cells. DNA fragmentation detection in breast adenocarcinoma MCF-7 cells showed that BSC triggered cell death is concentration and time dependent. We also show that two of these compounds, BSC 3g and 3n, cause cell-cycle arrest in the late G2/M in MCF-7 cells. Consistent with this, a reduction in CDK1 and CDK2 expression with no change in cyclin A an B1 was observed in this cell line. Activation of caspase-2 was also detected. However, the involvement of the caspase-dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pancaspase inhibitor z-VAD-fmk. Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after BSC 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.

Keywords: Bisacylimidoselenocarbamates, CDK1, Chk2, G2/M cell cycle arrest, MCF-7 breast cancer cells

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 20
ISSUE: 12
Year: 2013
Page: [1609 - 1619]
Pages: 11
DOI: 10.2174/0929867311320120010
Price: $58

Article Metrics

PDF: 9